With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.
Continue reading "For Novartis, 2012 Is Set To Be A Bumpy Ride" »
Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.
Continue reading "Austerity Holds Back VC Investing in European Biotech Companies in 2011" »
Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.
Continue reading "U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy" »
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
Continue reading "Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe" »
